Literature DB >> 24093840

Rheumatoid arthritis and cardiovascular disease.

Cynthia S Crowson1, Katherine P Liao, John M Davis, Daniel H Solomon, Eric L Matteson, Keith L Knutson, Mark A Hlatky, Sherine E Gabriel.   

Abstract

BACKGROUND: Rheumatic disease and heart disease share common underpinnings involving inflammation. The high levels of inflammation that characterize rheumatic diseases provide a "natural experiment" to help elucidate the mechanisms by which inflammation accelerates heart disease. Rheumatoid arthritis (RA) is the most common of the rheumatic diseases and has the best studied relationships with heart disease.
METHODS: A review of current literature on heart disease and RA was conducted.
RESULTS: Patients with RA have an increased risk of developing heart disease that is not fully explained by traditional cardiovascular risk factors. Therapies used to treat RA may also affect the development of heart disease; by suppressing inflammation, they may also reduce the risk of heart disease. However, their other effects, as in the case of steroids, may increase heart disease risk.
CONCLUSIONS: Investigations of the innate and adaptive immune responses occurring in RA may delineate novel mechanisms in the pathogenesis of heart disease and help identify novel therapeutic targets for the prevention and treatment of heart disease.
© 2013 Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 24093840      PMCID: PMC3890244          DOI: 10.1016/j.ahj.2013.07.010

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  79 in total

1.  EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis.

Authors:  M J L Peters; D P M Symmons; D McCarey; B A C Dijkmans; P Nicola; T K Kvien; I B McInnes; H Haentzschel; M A Gonzalez-Gay; S Provan; A Semb; P Sidiropoulos; G Kitas; Y M Smulders; M Soubrier; Z Szekanecz; N Sattar; M T Nurmohamed
Journal:  Ann Rheum Dis       Date:  2009-09-22       Impact factor: 19.103

2.  T-cell-mediated lysis of endothelial cells in acute coronary syndromes.

Authors:  Takako Nakajima; Stephanie Schulte; Kenneth J Warrington; Stephen L Kopecky; Robert L Frye; Jörg J Goronzy; Cornelia M Weyand
Journal:  Circulation       Date:  2002-02-05       Impact factor: 29.690

3.  Expansion of unusual CD4+ T cells in severe rheumatoid arthritis.

Authors:  P B Martens; J J Goronzy; D Schaid; C M Weyand
Journal:  Arthritis Rheum       Date:  1997-06

Review 4.  CD28 extinction in human T cells: altered functions and the program of T-cell senescence.

Authors:  Abbe N Vallejo
Journal:  Immunol Rev       Date:  2005-06       Impact factor: 12.988

5.  Incidence of noncardiac vascular disease in rheumatoid arthritis and relationship to extraarticular disease manifestations.

Authors:  Kimberly P Liang; Kelly V Liang; Eric L Matteson; Robyn L McClelland; Teresa J H Christianson; Carl Turesson
Journal:  Arthritis Rheum       Date:  2006-02

6.  Risk of venous thromboembolism in patients with rheumatoid arthritis and association with disease duration and hospitalization.

Authors:  Marie E Holmqvist; Martin Neovius; Jonas Eriksson; Ängla Mantel; Solveig Wållberg-Jonsson; Lennart T H Jacobsson; Johan Askling
Journal:  JAMA       Date:  2012-10-03       Impact factor: 56.272

Review 7.  Moving beyond JUPITER: will inhibiting inflammation reduce vascular event rates?

Authors:  Paul M Ridker
Journal:  Curr Atheroscler Rep       Date:  2013-01       Impact factor: 5.113

8.  Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis.

Authors:  David Hürlimann; Adrian Forster; Georg Noll; Frank Enseleit; Rémy Chenevard; Oliver Distler; Markus Béchir; Lukas E Spieker; Michel Neidhart; Beat A Michel; Renate E Gay; Thomas F Lüscher; Steffen Gay; Frank Ruschitzka
Journal:  Circulation       Date:  2002-10-22       Impact factor: 29.690

9.  Is a long-term high-intensity exercise program effective and safe in patients with rheumatoid arthritis? Results of a randomized controlled trial.

Authors:  Zuzana de Jong; Marten Munneke; Aeilko H Zwinderman; Herman M Kroon; Annemarie Jansen; Karel H Ronday; Dirkjan van Schaardenburg; Ben A C Dijkmans; Cornelia H M Van den Ende; Ferdinand C Breedveld; Theodora P M Vliet Vlieland; Johanna M W Hazes
Journal:  Arthritis Rheum       Date:  2003-09

Review 10.  Exercise training and cardiac rehabilitation in primary and secondary prevention of coronary heart disease.

Authors:  Carl J Lavie; Randal J Thomas; Ray W Squires; Thomas G Allison; Richard V Milani
Journal:  Mayo Clin Proc       Date:  2009-04       Impact factor: 7.616

View more
  88 in total

Review 1.  Functional neural-bone marrow pathways: implications in hypertension and cardiovascular disease.

Authors:  Jasenka Zubcevic; Monica M Santisteban; Teresa Pitts; David M Baekey; Pablo D Perez; Donald C Bolser; Marcelo Febo; Mohan K Raizada
Journal:  Hypertension       Date:  2014-03-31       Impact factor: 10.190

2.  Preventing Heart Failure in Inflammatory and Immune Disorders.

Authors:  Maya Serhal; Chris T Longenecker
Journal:  Curr Cardiovasc Risk Rep       Date:  2014-06

3.  Catechin ameliorates cardiac dysfunction in rats with chronic heart failure by regulating the balance between Th17 and Treg cells.

Authors:  Qi Zhang; Li-Qun Hu; Chang-Sen Yin; Ping Chen; Hong-Qi Li; Xin Sun; Guang Yan
Journal:  Inflamm Res       Date:  2014-04-24       Impact factor: 4.575

Review 4.  Impact of gut microbiota on gut-distal autoimmunity: a focus on T cells.

Authors:  Maran L Sprouse; Nicholas A Bates; Krysta M Felix; Hsin-Jung Joyce Wu
Journal:  Immunology       Date:  2019-01-21       Impact factor: 7.397

5.  Improved prediction of HIT in the SICU using an improved model of the Warkentin 4-T system: 3-T.

Authors:  Matthew B Bloom; Jeffrey Johnson; Oksana Volod; Ernest Y Lee; Terris White; Daniel R Margulies
Journal:  Am J Surg       Date:  2019-07-29       Impact factor: 2.565

6.  Risk of cardiovascular disease among patients with sarcoidosis: a population-based retrospective cohort study, 1976-2013.

Authors:  Patompong Ungprasert; Cynthia S Crowson; Eric L Matteson
Journal:  Eur Respir J       Date:  2017-02-23       Impact factor: 16.671

Review 7.  Atherosclerotic cardiovascular disease prevention in rheumatoid arthritis.

Authors:  Anne Grete Semb; Eirik Ikdahl; Grunde Wibetoe; Cynthia Crowson; Silvia Rollefstad
Journal:  Nat Rev Rheumatol       Date:  2020-06-03       Impact factor: 20.543

Review 8.  Cardiovascular risk in rheumatoid arthritis: assessment, management and next steps.

Authors:  Thomas Zegkos; George Kitas; Theodoros Dimitroulas
Journal:  Ther Adv Musculoskelet Dis       Date:  2016-04-30       Impact factor: 5.346

9.  Asymmetric and symmetric dimethylarginine concentration as an indicator of cardiovascular diseases in rheumatoid arthritis patients: a systematic review and meta-analysis of case-control studies.

Authors:  Parisa Zafari; Ahmadreza Zarifian; Reza Alizadeh-Navaei; Mahdi Taghadosi; Alireza Rafiei; Zahra Samimi; Fatemeh Niksolat
Journal:  Clin Rheumatol       Date:  2019-08-03       Impact factor: 2.980

10.  Heterogeneity of peripheral blood monocytes, endothelial dysfunction and subclinical atherosclerosis in patients with systemic lupus erythematosus.

Authors:  T P Mikołajczyk; G Osmenda; B Batko; G Wilk; M Krezelok; D Skiba; T Sliwa; J R Pryjma; T J Guzik
Journal:  Lupus       Date:  2015-08-06       Impact factor: 2.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.